Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Field Test

NCT05852730 is registered in ClinicalTrials.gov with Repurposed Therapeutics, Inc. as lead sponsor.

NCT NCT05852730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05852730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Field Test
Lead sponsor
Repurposed Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 10, 2021
Completion date
September 30, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

motion sickness, space, motion simulation, parabolic flight